MDNA-11 is under clinical development by Medicenna Therapeutics and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MDNA-11 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MDNA-11 overview

MDNA-11 was under development for the treatment of advanced solid tumors including metastatic melanoma, renal cell carcinoma, sarcoma, triple negative breast cancer, pancreatic ductal adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, colorectal cancer, gastric cancer, biliary tract cancer, gallbladder cancer, cholangiocarcinoma, uterine cancer, epithelial ovarian cancer, cervical cancer, basal cell carcinoma, bladder cancer, Merkle cell carcinoma, squamous cell carcinoma of head and neck and cutaneous squamous cell carcinoma. The drug candidate is a long-acting IL-2 variant engineered to have enhanced affinity to CD122 without interacting with CD25. It is administered by intravenous infusion and is developed based on Medicenna’s empowered cytokines (EC) and BiSKITs (Bi-functional SuperKine ImmunoTherapies) platform.

Medicenna Therapeutics overview

Medicenna Therapeutics (Medicenna), formerly A2 Acquisition, is a clinical-stage immuno-oncology company developing empowered cytokines (EC) and first-in-class, interleukins (IL-2, IL-4 and IL-13) superkines for the treatment of cancer. The company’s pipeline products include MDNA55, IL-4 cytokine for recurrent glioblastoma and other brain and non-brain tumors; MDNA11, targeting solid tumors and non-malignant cells; BISKIT and others. It develops cytokines to deliver cell-killing payloads to the bulk tumor, tumor microenvironment, and cancer stem cells. The company offers its products in therapeutic areas of oncology including CNS cancers in glioblastoma multiforme, brain metastasis, pediatric glioma, blood cancers, solid tumors and bladder cancers. It has operations in Canada and the US. Medicenna is headquartered in Toronto, Ontario, Canada.

For a complete picture of MDNA-11’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.